Heyza JR - Search Results

1

Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer.

Heyza JR, Lei W, Watza D, Zhang H, Chen W, Back JB, Schwartz AG, Bepler G, Patrick SM. Heyza JR, et al. Clin Cancer Res. 2019 Apr 15;25(8):2523-2536. doi: 10.1158/1078-0432.CCR-18-3094. Epub 2018 Dec 11. Clin Cancer Res. 2019. PMID: 30538112 Free PMC article.

2

Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.

Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM. Heyza JR, et al. Nutrients. 2018 Nov 3;10(11):1644. doi: 10.3390/nu10111644. Nutrients. 2018. PMID: 30400270 Free PMC article.

3

Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.

Arora S, Heyza J, Zhang H, Kalman-Maltese V, Tillison K, Floyd AM, Chalfin EM, Bepler G, Patrick SM. Arora S, et al. Oncotarget. 2016 Nov 15;7(46):75104-75117. doi: 10.18632/oncotarget.12072. Oncotarget. 2016. PMID: 27650543 Free PMC article.

4

Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.

Feldmann DP, Heyza J, Zimmermann CM, Patrick SM, Merkel OM. Feldmann DP, et al. Molecules. 2020 Apr 24;25(8):1994. doi: 10.3390/molecules25081994. Molecules. 2020. PMID: 32344513 Free PMC article.

5

The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.

Hu C, Zhang M, Moses N, Hu CL, Polin L, Chen W, Jang H, Heyza J, Malysa A, Caruso JA, Xiang S, Patrick S, Stemmer P, Lou Z, Bai W, Wang C, Bepler G, Zhang XM. Hu C, et al. Cell Death Dis. 2020 May 7;11(5):328. doi: 10.1038/s41419-020-2519-8. Cell Death Dis. 2020. PMID: 32382008 Free PMC article.

6

Gap Junction Intercellular Communication Positively Regulates Cisplatin Toxicity by Inducing DNA Damage through Bystander Signaling.

Arora S, Heyza JR, Chalfin EC, Ruch RJ, Patrick SM. Arora S, et al. Among authors: heyza jr. Cancers (Basel). 2018 Oct 2;10(10):368. doi: 10.3390/cancers10100368. Cancers (Basel). 2018. PMID: 30279363 Free PMC article.

7

In Vivo Targeting Replication Protein A for Cancer Therapy.

VanderVere-Carozza PS, Gavande NS, Jalal SI, Pollok KE, Ekinci E, Heyza J, Patrick SM, Masters A, Turchi JJ, Pawelczak KS. VanderVere-Carozza PS, et al. Front Oncol. 2022 Feb 18;12:826655. doi: 10.3389/fonc.2022.826655. eCollection 2022. Front Oncol. 2022. PMID: 35251993 Free PMC article.

8

Pathomimetic cancer avatars for live-cell imaging of protease activity.

Ji K, Heyza J, Cavallo-Medved D, Sloane BF. Ji K, et al. Biochimie. 2016 Mar;122:68-76. doi: 10.1016/j.biochi.2015.09.015. Epub 2015 Sep 12. Biochimie. 2016. PMID: 26375517 Free PMC article. Review.

9

Single-molecule imaging reveals the kinetics of non-homologous end-joining in living cells.

Mikhova M, Goff NJ, Janovič T, Heyza JR, Meek K, Schmidt JC. Mikhova M, et al. Among authors: heyza jr. Nat Commun. 2024 Nov 23;15(1):10159. doi: 10.1038/s41467-024-54545-y. Nat Commun. 2024. PMID: 39578493 Free PMC article.

10

Single-molecule imaging reveals the kinetics of non-homologous end-joining in living cells.

Mikhova M, Goff NJ, Janovič T, Heyza JR, Meek K, Schmidt JC. Mikhova M, et al. Among authors: heyza jr. bioRxiv [Preprint]. 2024 May 25:2023.06.22.546088. doi: 10.1101/2023.06.22.546088. bioRxiv. 2024. Update in: Nat Commun. 2024 Nov 23;15(1):10159. doi: 10.1038/s41467-024-54545-y PMID: 38826211 Free PMC article. Updated. Preprint.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters